Beckman Coulter Life Sciences
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- Danaher to launch AI autonomous lab with up to 8x faster antibody reagent development
Danaher announced it will launch its first AI-powered autonomous research lab, based at its reagent subsidiary Abcam and combining AI, robotics and technologies from subsidiaries including Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies and Molecular Devices, with instrument coordination and robotic automation co-developed with Automata, which Danaher invested in during January 2026; full-scale operation is expected in early 2027. In the loop, AI first designs affinity reagents such as antibodies that bind biological targets, robots build and test them, and results are fed back to the models to improve the next design round. Danaher says the approach can speed up the path from concept to validated reagent by up to 8x and lift annual reagent output up to 10x, from dozens to hundreds of reagents — figures that are the company's own projections.
科技新报 · 🔥 0
Experience and discussion from the community
Share my Beckman Coulter Life Sciences experienceAsk about Beckman Coulter Life Sciences
Nobody has shared their experience with Beckman Coulter Life Sciences yet.